Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05739981
Title A Phase II Study Evaluating the Effect of GEN-1 on SLL When Administered in Combination With Bevacizumab and NACT in Subjects Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (MRD)
Acronym MRD
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Imunon
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Johns Hopkins Medicine SKCCC RECRUITING Baltimore Maryland 21231 United States Details
Memorial Sloan Kettering Cancer Center RECRUITING New York New York 10065 United States Details
University of Texas MD Anderson Cancer Center RECRUITING Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field